The tuberous sclerosis complex genes TSC1 and TSC2 were first identified by positional cloning strategies in the heritable human disorder tuberous sclerosis. They encode previously unknown proteins, termed hamartin and tuberin respectively, that form a functional complex. The phenotypic manifestations of tuberous sclerosis are extremely diverse and suggest normal roles for TSC1 and TSC2 in regulating the growth, proliferation, migration and differentiation of many cell types. Investigations of TSC1 and TSC2 in a number of model organisms and cell-culture systems have provided new insights into the mechanisms through which these roles are effected. Most promisingly, the hamartin-tuberin complex has been shown to function as a negtive regulator of the insulin receptor/phosphoinositide 3-kinase/S6 kinase pathway. Drugs that act to inhibit this pathway may have therapeutic potential for tuberous sclerosis and the related disorder lymphangioleiomyomatosis.
Tuberous sclerosis
Tuberous sclerosis is an autosomal dominant disorder that is recognized in approx. 1 in 10 000 live births and that occurs in all ethnic groups. Some 60% of cases are sporadic and the mutation rate has been estimated at 2.5 × 10 −5 /gamete [1] . Tuberous sclerosis is characterized by the development of multiple hamartomas. These are growths comprising a variety of dysplastic cell types that rarely become malignant. Virtually all organs and tissues may be involved. Cortical tubers, sub-ependymal nodules and sub-ependymal giant cell astrocytomas (SEGAs) are the hallmarks in the central nervous system of tuberous sclerosis [2] . Abnormal white matter migration tracks, abnormalities of myelination and cerebellar lesions similar to tubers also occur. Tubers are discrete areas of loss of normal cortical architecture characterized by a loss of gyral and sulcal modelling and of normal hexalaminar organization. The cellular componants include highly characteristic large and morphologically abnormal neurons and balloon cells. Nodular irregularities of the sub-ependymal region lining the lateral ventricles (subependymal nodules) are seen in most patients. In around 5% of patients, these develop into larger tumours classified as SEGAs, typically in childhood or early adult life. By contrast the other macroscopic brain lesions do not usually enlarge after completion of brain growth. Brain involvement leads to frequent and severe clinical features including epilepsy (approx. 80% of patients), intellectual handicap (up to 50%) and autism and other behavioural abnormalities (over 50%) [2] .
Renal lesions include angiomyolipomas, cysts and renal cell carcinoma. Angiomyolipomas are the most frequent, being present in 50-80% of patients by 10 years of age [3] . Severe involvement appears to be more common in females, perhaps reflecting hormonally promoted growth, since expression of oestrogen and progesterone receptors has been demonstrated in angiomyolipomas [4] . These hamatromas contain fat, abnormal smooth muscle-like cells and disorganized vessels. Malignant angiomyolipoma or renal cell carcinoma occur infrequently but may be bilateral and multifocal and can occur at an early age [5] . Simple renal cysts are frequent in tuberous sclerosis, but in a small percentage of patients, the kidneys are enlarged and severely polycystic. The cystic epithelium is highly characteristic, comprising enlarged cells with strongly eosinophilic cytoplasm [6] .
Lymphangioleiomyomatosis (LAM) is an obstructive infiltration of alveolar septae, bronchioles, lymphatics and blood vessels by smooth muscle-like cells with morphological and immunocytochemical characteristics similar to some of the cells seen in angiomyolipomas. Some 2-3% of patients with tuberous sclerosis, almost exclusively post-pubertal females, have syptomatic respiratory disease due to LAM, but a much higher proportion of female patients have subclinical disease [7] . A sporadic form of LAM with lung, and sometimes kidney and lymph node involvement, but without other signs of tuberous sclerosis is recognized in approx. 1 in 500 000 females.
The skin is involved in most patients with tuberous sclerosis. Manifestations include angiofibromas affecting the face and nail beds (ungual fibromas), fibromatous plaques of the forehead and scalp, collagenous hamartomas of the dermis, termed shagreen patches, hypopigmented macules and skin tags (moluscum fibrosum pendulum) [2] .
Benign cardiac hamartomas called rhabdomyomas develop during fetal life and can be detected by echocardiography in approx. 60-80% of infants and children with tuberous sclerosis. They comprised large cells that resemble cardiac myoblasts. During postnatal life the tumours involute or become relatively smaller as the heart grows [2] . Critically located tumours may cause cardiac failure or arrhythmia.
Other phenotypic manifestations are less common or of lesser clinical importance and include hepatic and splenic haemangiomas, hamartomatous polyps of the large bowel, aneurysms of the aorta and large arteries, bony sclerosis and cysts, pits affecting the dental enamel and rarely endocrine hamartomas and tumours [2] .
Clinical diagnosis of tuberous sclerosis is based on features identified by physical examination and by radiographical and histopathological investigation and relies on the identification of two or more different and independent tuberous sclerosisassociated hamartomas [8] .
The wide range of phenotypic manifestations of tuberous sclerosis has attracted the attention of medical scientists with a diverse range of interests, particularly neuroscientists. However, it was not until the TSC1 and TSC2 genes were identified that directed experimental approaches could be devised to understand better the origins of the tuberous sclerosis phenotype and gain insights into the associated normal biological processes.
The tuberous sclerosis complex genes TSC1 and TSC2

Identification and characterization of TSC2
TSC2 was localized to human chromosome 16p13.3 by systematic genome-wide linkage analysis. Further positional information was obtained by analysis of deletions of 16p13.3-pter in two patients, one with and one without tuberous sclerosis [2, 9] . Together these rearrangements implicated a 300 kb region that was cloned as a set of overlapping cosmids and screened for rearrangements in a large panel of unrelated patients with tuberous sclerosis using pulsedfield gel analysis. Five deletion mutations were characterized, all involving a 120 kb area from which four genes were identified. One gene was disrupted by all five deletions, making it a strong candidate for TSC2. The identification of several intragenic tuberous sclerosis-associated deletions by conventional Southern analysis then confirmed the identify of TSC2 [9] . The gene comprises 41 coding exons and one leader exon [10] . Exons 25, 26 and 31 are subject to alternative splicing [10] . The encoded protein tuberin has a full-length isoform of 1807 amino acids (198 kDa). A region spanning residues 1517-1674 and encoded by exons 34-38 has significant homology to the GTPase-activiating proteins ('GAPs') human rap1GAP and murine Spa1 [9, 11] . However, only modest GTPase-activiating protein activity of tuberin for rap1 and rab5 has been demonstrated biochemically [12, 13] , and it is unclear whether these activities are of physiological importance.
Identification and characterization of TSC1
TSC1 was localized to a region of approx. 1.5 Mb by linkage studies. This was cloned as a series of overlapping cosmid and P1 artificial chromosome clones for molecular genetic characterization. In contrast to findings at the TSC2 locus, screens for large rearrangements and analysis of many candidate genes from the TSC1 region proved negative [14] . Genomic sequencing of the region enabled the systematic identification of exons that were then screened for mutations in patients with tuberous sclerosis. A predicted exon that contained frameshift mutations in affected individuals was identified and further analysis characterized a gene comprising 23 exons, of which 3-23 were coding and contained many distinct mutations in patients with tuberous sclerosis, confirming its identity as TSC1 [14] . Hamartin, the predicted product, comprised 1164 amino acids (130 kDa). It had no significant homology to tuberin or other known vertebrate proteins but did have significant homology to a Schizosaccharomyces pombe predicted protein (GenBank R accession number Q09778). It also contained strongly predicted coiled-coil domains (residues 730-965) [15] .
TSC1 and TSC2 mutations
Germline mutations of TSC1 and TSC2
A wide spectrum of germline mutations of TSC1 and TSC2 have been reported in association with the tuberous sclerosis phenotype. Over 400 mutations have been reported with relatively few recurrent mutations [10] . Databases of mutations at the TSC1 and TSC2 loci include the Human Gene Mutation Database (http://www.uwcm.ac.uk/uwcm/ mg/hgmd0.html) and a TSC-gene-specific database (http:// expmed.bwh.harvard.edu/ts/).
Germline mutations at the TSC2 locus are found more frequently than TSC1 mutations in sporadic cases of tuberous sclerosis. They include multi-exon and whole-gene deletions, missense changes, nonsense mutations, small insertions and deletions and splice-site changes distributed throughout the gene ( [10] and Table 1 ). TSC1 mutations are found in only 20% of TSC probands and include mainly micro-deletions, nonsense changes, insertions and splice-site changes, virtually all of which are predicted to be truncating. They are distributed throughout the coding region, with the majority occurring in exons 15-21 ([10] and Table 1 ). TSC1 mutations are significantly under-represented in sporadic as opposed to familial cases and manifestations of tuberous sclerosis appear to be less severe among TSC1 than TSC2 cases [10] . These observations would be consistent with lower germline and somatic mutation rates for TSC1 than TSC2.
There are a number of reports of germline and somatic mosaicism at the TSC1 and TSC2 loci and somatic mosaicism may be present in 10% or more of new mutation cases, posing a significant challenge for molecular genetic diagnostics [16] . 
A contiguous gene-deletion syndrome involving TSC2 and the polycystic kidney disease 1 gene (PKD1)
The TSC2 gene lies immediately adjacent to the PKD1 gene that is mutated in autosomal dominant polycystic kidney disease type 1. The genes are arranged 3 to 3 with their polyadenylation signals only 60 bp apart. Deletion mutations at the locus may involve both genes and a contiguous gene-deletion syndrome of tuberous sclerosis and polycystic kidney disease has been defined [17] . This is often associated with early onset and severe renal cystic disease, which may be diagnosed in utero or shortly after birth and lead to end-stage renal failure by late childhood or early adult life [17] .
Somatic mutations of TSC1 and TSC2 in hamartomas
Hamartomas from patients with tuberous sclerosis, including angiomyolipomas, rhabdomyomas, SEGAs and angiofibromas, may show loss of heterozygosity (LOH) at one or other TSC locus, consistent with the classification of both genes as Knudson-type tumour suppressors. LOH has been observed less frequently at the TSC1 locus than at the TSC2 locus, as expected given the small proportion of patients with germline TSC1 mutations. There is little evidence for LOH in cortical tubers [18] , possibly reflecting the mixture of phenotypically normal and abnormal cells evident in these lesions on histopathological examination [2] . Both LOH and intragenic mutation of the TSC1 gene have been reported in tuberous sclerosis-associated renal cell carcinoma [14] . LOH and somatic mutations involving the TSC1 and TSC2 genes have also been sought in sporadic hamartomas and tumours. LOH and intragenic mutations at the TSC2 locus have been reported in sporadic angiomyolipomas [19] and in sporadic LAM [20] . Although reduced or absent expression of tuberin has been reported in a variety of other sporadic tumours, further evidence of bi-alleic inactivation by deletion, intragenic mutation or epigenetic mechanisms is needed to confirm direct involvement of the TSC genes themselves.
Animal models
Mouse and Drosophila models carrying mutant TSC1 and TSC2 alleles have been reported, as has a naturally occurring TSC2 mutant rat, the 'Eker' rat. These models have provided a valuable resource for investigating the functions of TSC1 and TSC2.
Eker rat
The Eker rat carries an inactivating retrotransposon insertion mutation in exon 30 of the Tsc2 gene [21,21a] . It develops bilateral multifocal solid and cystic renal adenomas and extra-renal pathology, including uterine leiomyoma, splenic haemangioma, pituitary adenoma and sub-ependymal hamartomas in the brain [22] . The phenotype is transmitted as an autosomal dominant trait with embryonic lethality in the homozygote at days 10-12 with disrupted neuroepithelial growth and development [23] . Allelic loss and intragenic mutation have been demonstrated in tumours in the Eker rat [24] and transgenic expression of Tsc2 in the Eker rat and Eker tumour cell lines support its tumour-suppressor function [25] .
Tsc1-and Tsc2-knockout mice
Mice with targeted disruption of Tsc1 or Tsc2 have been generated and express a phenotype similar to the Eker rat [26] [27] [28] [29] . Multiple renal cystadenomas develop and lead to renal cell carcinoma in approx. 5-15% of mice by 18-24 months. Although there is considerable inter-strain variability in tumour development this appears to be more rapid in Tsc2 than Tsc1 heterozygotes. Histologically benign hepatic haemangiomas and histologically malignant but non-metastasizing haemangiosarcomas of the limbs and tail also occur. Lung adenomas have also been observed, but seem to have limited growth potential. Homozygotes die in mid-gestation (E10.5-E12.5) and exhibit growth failure, hepatic hypoplsia, cardiac hypertrophy and anaemia.
Drosophila
Homozygous mutations of the tsc2 gene are lethal to Drosophila during larval development. However, tsc2 −/− clones generated in specific tissues exhibit the 'gigas' phenotype characterized by increased cell and organ size with generally normal differentiation and morphology [30] . Mutagenesis screens have revealed that tsc1 mutations also cause a gigaslike phenotype [31] [32] [33] .
Functional analysis of TSC1 and TSC2
A direct interaction between mammalian hamartin and tuberin has been demonstrated by assays using the yeast two-hybrid system and by co-immunoprecipitation [15] . A functional interaction has also been demonstrated in Drosophila [31] [32] [33] . Abrogation of the interaction has been observed with tuberous sclerosis-associated mutant forms of either protein [34] . Co-fractionation experiments are consistent with hamartin and tuberin forming a predominantly cytosolic complex, although a small proportion of both proteins appears to be membrane-associated [35] . Initial clues as to the roles of hamartin and tuberin were gained through antisense inhibition of their expression that resulted in quiescent G 0 -arrested fibroblasts undergoing cyclindependent kinase ('CDK')-dependent re-entry into the cell cycle [36, 37] . Inhibition of TSC2 expression also appeared to inhibit neuronal differentiation in culture [38] . Conversely, overexpression of either protein was found to cause growth arrest [36, 37] . Other clues to potential functions came from protein-protein interactions observed in yeast two-hybrid screens that identified rabaptin as a potential binding partner for tuberin and ezrin for hamartin [39, 40] . Abnormalities of Rho activation and changes of the actin cytoskeleton have been reported in cells deficient or depleted in hamartin, consistent with a physiological role for TSC1 in cell adhesion and migration [40, 41] . Others have provided evidence of roles for tuberin in transcriptional activation [42] [43] [44] .
Most compellingly, genetic analyses in Drosophila have revealed robust evidence that Tsc1 and Tsc2 regulate cell size via the insulin receptor/phosphoinositide 3-kinase/Akt/S6 kinase pathway [31] [32] [33] . Recent reports show that TSC1-TSC2 also regulates S6 kinase in mammalian cells [45] [46] [47] [48] [49] . The TSC1-TSC2 complex appears to act downstream of the insulin receptor, phosphoinositide 3-kinase and AKT1 to inhibit phosphorylation of S6 kinase and the translation initiation factor 4E-binding protein 1 ('4E-BP1'). Regulation may be effected at the level of mammalian target of rapamycin (mTOR) (Figure 1) . Rapamycin is an inhibitor of mTOR and blocks phosphorylation of S6 kinase in TSC2-deficient cells as well as normal cells.
Proliferation of TSC2
−/− cells appears highly sensitive to rapamycin [48] and the results of clinical trials in patients with tuberous sclerosis and sporadic LAM are now eagerly awaited.
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